Sistema de Salut de Catalunya
Institut Català de la Salut
[Budde LE] City of Hope National Medical Center, Duarte, CA. [Assouline S] Jewish General Hospital and McGill University, Montreal, Quebec, Canada. [Sehn LH] BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada. [Schuster SJ] Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. [Yoon SS] Seoul National University Hospital, Seoul, South Korea. [Yoon DH] Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Bosch F] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-07-01T10:44:51Z
2024-07-01T10:44:51Z
2024-07-01
Mosunetuzumab; B-cell non-Hodgkin lymphomas; Relapsed
Mosunetuzumab; Limfomes no Hodgkin de cèl·lules B; Recaiguda
Mosunetuzumab; Linfomas no Hodgkin de células B; Recaída
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Mosunetuzumab is a CD20xCD3 T-cell–engaging bispecific antibody administered as an off-the-shelf, fixed-duration treatment in an outpatient setting. We report an updated analysis of the durability of response, by investigator assessment, after an overall median follow-up of 3.5 years in patients with relapsed/refractory indolent or aggressive B-cell non-Hodgkin lymphoma (iNHL/aNHL) from the dose-escalation stage of a phase I/II study of mosunetuzumab (ClinicalTrials.gov identifier: NCT02500407). Across dose levels, 65.7% of patients with iNHL and 36.4% with aNHL achieved a complete or partial response to mosunetuzumab. Median duration of response (DoR) in patients with iNHL for all responders was 23.2 months (95% CI, 13.8 to not estimable [NE]), but was not reached in complete responders (95% CI, 21.0 to NE). After a median time on study of 38.9 months, no relapses were observed beyond 26 months in complete responders. In patients with aNHL, median DoR for all responders was 7.8 months (95% CI, 4.6 to 22.8). Among 12 complete responders who progressed postmosunetuzumab treatment and were retreated with mosunetuzumab, 83.3% had an objective response and 58.3% achieved a second complete response. Our study reports the longest follow-up using bispecific antibodies in patients with B-cell non-Hodgkin lymphoma and demonstrates that mosunetuzumab can mediate durable remissions with time-limited treatment.
Supported by Genentech, Inc.
Article
Published version
English
Cèl·lules B - Tumors - Tractament; Limfomes - Tractament; Anticossos monoclonals - Ús terapèutic; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell; Other subheadings::Other subheadings::Other subheadings::/drug therapy; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
American Society of Clinical Oncology
Journal of Clinical Oncology;42(19)
https://doi.org/10.1200/JCO.23.02329
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
